Ascendis Pharma A/S (ASND)
NASDAQ: ASND · IEX Real-Time Price · USD
136.93
-6.25 (-4.37%)
Apr 25, 2024, 4:00 PM EDT - Market closed
Ascendis Pharma Balance Sheet
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
| Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 - 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 392.16 | 444.77 | 446.27 | 584.52 | 598.11 | 277.86 | 195.35 | 180.33 | 119.65 | 50.17 | Upgrade
|
| Short-Term Investments | 7.28 | 290.69 | 235.8 | 134.28 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Cash & Cash Equivalents | 399.44 | 735.46 | 682.06 | 718.8 | 598.11 | 277.86 | 195.35 | 180.33 | 119.65 | 50.17 | Upgrade
|
| Cash Growth | -45.69% | 7.83% | -5.11% | 20.18% | 115.25% | 42.24% | 8.33% | 50.72% | 138.50% | 158.19% | Upgrade
|
| Receivables | 57.1 | 26.66 | 24.1 | 8.72 | 6.88 | 1.78 | 1.6 | 0.93 | 1.4 | 1.5 | Upgrade
|
| Inventory | 208.93 | 130.67 | 75.41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Current Assets | 37.25 | 30.68 | 24.32 | 12.62 | 6.19 | 13.26 | 7.69 | 2.7 | 4.6 | 1.49 | Upgrade
|
| Total Current Assets | 702.72 | 923.47 | 805.89 | 740.13 | 611.17 | 292.91 | 204.63 | 183.96 | 125.65 | 53.16 | Upgrade
|
| Property, Plant & Equipment | 110.63 | 129.1 | 126.05 | 108.11 | 45.07 | 4.33 | 2.56 | 2.35 | 2.36 | 1.87 | Upgrade
|
| Long-Term Investments | 5.69 | 30.42 | 145.91 | 124.46 | 15.54 | 18.24 | 0.29 | 0.27 | 0.27 | 0.14 | Upgrade
|
| Goodwill and Intangibles | 4.42 | 4.83 | 5.27 | 5.72 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | Upgrade
|
| Other Long-Term Assets | 2.13 | 1.92 | 1.81 | 1.38 | 1.46 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Total Long-Term Assets | 122.87 | 166.27 | 279.04 | 239.66 | 65.57 | 26.06 | 6.35 | 6.11 | 6.12 | 5.51 | Upgrade
|
| Total Assets | 825.59 | 1,090 | 1,085 | 979.79 | 676.73 | 318.97 | 210.98 | 190.07 | 131.77 | 58.67 | Upgrade
|
| Accounts Payable | 94.57 | 101.03 | 59.42 | 21.9 | 27.77 | 32.01 | 23.77 | 13.08 | 8.37 | 4.96 | Upgrade
|
| Deferred Revenue | 7.13 | 14.21 | 5.57 | 0.36 | 0.86 | 6.9 | 0 | 0.09 | 3.07 | 7.91 | Upgrade
|
| Current Debt | 25.4 | 25.42 | 7 | 6.86 | 5.9 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Current Liabilities | 70.25 | 30.61 | 28.38 | 23.69 | 13.47 | 0.01 | 0 | 0.29 | 0 | 0 | Upgrade
|
| Total Current Liabilities | 197.34 | 171.27 | 100.36 | 52.8 | 47.99 | 38.92 | 23.77 | 13.46 | 11.45 | 12.86 | Upgrade
|
| Long-Term Debt | 618.87 | 482.96 | 97.97 | 85.12 | 30.72 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Other Long-Term Liabilities | 155.08 | 172.16 | 2.96 | 3.16 | 0.91 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Total Long-Term Liabilities | 773.94 | 655.12 | 100.93 | 88.28 | 31.63 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Total Liabilities | 971.28 | 826.39 | 201.29 | 141.08 | 79.62 | 38.92 | 23.77 | 13.46 | 11.45 | 12.86 | Upgrade
|
| Total Debt | 644.27 | 508.38 | 104.96 | 91.98 | 36.62 | 0 | 0 | 0 | 0 | 0 | Upgrade
|
| Debt Growth | 26.73% | 384.35% | 14.12% | 151.17% | - | - | - | - | - | - | Upgrade
|
| Retained Earnings | -153.45 | 255.67 | 875.99 | 831.49 | 590.67 | 274.39 | 182.24 | 172.26 | 111.28 | 39.56 | Upgrade
|
| Shareholders' Equity | -145.7 | 263.35 | 883.64 | 838.71 | 597.11 | 280.05 | 187.21 | 176.61 | 120.33 | 45.81 | Upgrade
|
| Net Cash / Debt | -244.83 | 227.08 | 577.1 | 626.82 | 561.49 | 277.86 | 195.35 | 180.33 | 119.65 | 50.17 | Upgrade
|
| Net Cash / Debt Growth | - | -60.65% | -7.93% | 11.64% | 102.07% | 42.24% | 8.33% | 50.72% | 138.50% | 158.19% | Upgrade
|
| Net Cash Per Share | -4.35 | 4.05 | 10.54 | 12.38 | 12.07 | 6.76 | 5.81 | 6.79 | 5.03 | 4.40 | Upgrade
|
| Working Capital | 505.38 | 752.2 | 705.53 | 687.33 | 563.18 | 253.99 | 180.87 | 170.5 | 114.21 | 40.3 | Upgrade
|
| Book Value Per Share | -2.59 | 4.70 | 16.13 | 16.57 | 12.84 | 6.82 | 5.57 | 6.65 | 5.06 | 4.02 | Upgrade
|
Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).